OLFML2B Antibody

Introduction to OLFML2B Antibody

OLFML2B antibodies are immunological reagents specifically designed for the detection and analysis of olfactomedin-like 2B (OLFML2B) protein in various research and diagnostic applications. These antibodies bind to specific epitopes on the OLFML2B protein, allowing for its identification, quantification, and characterization in biological samples . As research tools, they have become increasingly valuable in understanding the normal biological functions of OLFML2B and its role in pathological conditions.

Commercial OLFML2B antibodies are available from numerous suppliers in various formats, including monoclonal and polyclonal varieties, with different specificities for species ranging from human to various animal models . The diversity of available antibodies allows researchers to select products optimized for their specific experimental needs, whether they're conducting basic protein detection or complex immunohistochemical analyses.

The OLFML2B Protein Target

Before discussing the antibodies themselves, it's essential to understand their target. OLFML2B (olfactomedin-like protein 2B, also known as photomedin-2) is a secreted glycoprotein with a canonical length of 750 amino acid residues and a molecular mass of approximately 84 kDa in humans . The protein belongs to the olfactomedin domain-containing protein family and has been reported to exist in up to two different isoforms .

OLFML2B is widely expressed throughout the body, with notable presence in the appendix, cerebral cortex, and cardiac tissue . At the molecular level, OLFML2B undergoes several post-translational modifications, including O-glycosylation and N-glycosylation, which may affect its functionality and interactions . Evolutionary conservation of OLFML2B is evident through identified orthologs in multiple species, including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken .

Antibody Classification and Production

OLFML2B antibodies can be classified based on several characteristics:

Custom-made monoclonal antibodies have been developed for specialized research, such as the rat anti-human OLFML2B monoclonal antibodies (7C4, IgG2a) that have shown optimal results in Western blot analysis of OLFML2B .

Applications and Techniques

OLFML2B antibodies find utility across numerous laboratory techniques:

1. Western Blot (WB): The most common application, allowing for protein detection based on molecular weight .

2. Enzyme-Linked Immunosorbent Assay (ELISA): Enables quantitative measurement of OLFML2B in solution .

3. Immunohistochemistry (IHC): Facilitates visualization of OLFML2B distribution in tissue sections .

4. Immunofluorescence (IF): Allows high-resolution localization studies using fluorescent detection .

5. Immunocytochemistry (ICC): Permits OLFML2B visualization in cultured cells .

Researchers must select antibodies validated for their specific application to ensure reliable results. Many commercial antibodies undergo validation across multiple applications, with data provided in product documentation .

OLFML2B in Cancer Research

The application of OLFML2B antibodies has significantly contributed to understanding this protein's role in oncology, revealing its potential as both a prognostic marker and therapeutic target.

OLFML2B as a Prognostic Biomarker in Bladder Cancer

Recent research has identified OLFML2B as a robust prognostic biomarker for bladder cancer. Using antibody-based detection methods, studies have demonstrated that patients with high OLFML2B expression exhibit poorer prognosis compared to those with lower expression levels . This association remains consistent across multiple cohorts, confirming OLFML2B's reliability as a prognostic indicator.

The expression of OLFML2B increases proportionally with bladder cancer stage and grade, suggesting its potential utility in monitoring disease progression . Functional studies using bladder cancer cell lines have shown that knockdown of OLFML2B resulted in decreased migration and proliferation capabilities, indicating its direct involvement in cancer cell behavior .

Pan-Cancer Analysis of OLFML2B Expression

Beyond bladder cancer, OLFML2B has emerged as a significant factor across multiple cancer types. Comprehensive pan-cancer analysis has revealed:

1. OLFML2B is overexpressed in at least 14 different cancer types compared to corresponding normal tissues .

2. High OLFML2B expression correlates with poor prognosis in multiple cancer types .

3. Expression levels have been validated in hepatocellular carcinoma cell lines, confirming the utility of OLFML2B antibodies for detection in liver cancer models .

This broad oncological significance positions OLFML2B as a potential pan-cancer biomarker worthy of further investigation. Specifically, in rats, OLFML2B has been associated with hepatocellular carcinoma and experimental liver cirrhosis, suggesting its relevance in liver pathologies .

Immune Infiltration and Tumor Microenvironment

Perhaps most intriguingly, antibody-based research has uncovered OLFML2B's relationship with the tumor immune microenvironment. OLFML2B expression:

1. Positively correlates with macrophage infiltration in tumor tissues .

2. Shows high co-expression with tumor-associated macrophage markers .

3. Associates with tumor mutational burden (TMB) in 13 cancer types and microsatellite instability (MSI) in 10 cancer types .

4. May influence immune-related pathways including leukocyte transendothelial migration .

These findings suggest OLFML2B may modulate tumor-immune interactions, potentially affecting immunotherapy responses. Additionally, OLFML2B may impact cancer therapy by increasing resistance to certain drugs, including binimetinib, cobimentinib, and trametinib .

OLFML2B in Cardiovascular Research

Beyond oncology, OLFML2B antibodies have facilitated important discoveries in cardiovascular research, revealing this protein's presence and function in cardiac tissue.

Cardiac Expression and Protein Interactions

Immunodetection methods have confirmed OLFML2B expression in human heart tissue . Mass spectrometric analysis identified Tenascin C (TNC) as an interaction partner of OLFML2B . This interaction is particularly notable because TNC:

1. Is abundantly expressed during embryonic development

2. Shows limited expression in adults except during periods of high mechanical stress

3. Has been demonstrated to impair the inactivation of sodium channels

4. May influence cardiac injuries through its interaction with OLFML2B

The OLFML2B-TNC interaction provides important context for understanding cardiac repolarization and potential mechanisms for arrhythmogenesis.

OLFML2B Mutations and Cardiac Conditions

Research utilizing OLFML2B antibodies has identified mutations in patients with various cardiac conditions, including:

1. Atrial fibrillation (AF)

2. Ventricular arrhythmias (LQT)

3. Dilated cardiomyopathy (DCM)

4. Sudden infant death syndrome (SIDS)

Functional characterization of these mutations revealed temperature-dependent secretion abnormalities. Poorly secreted OLFML2B variants were rare at the population level and found exclusively in patients with SIDS, AF, or LQT . This suggests OLFML2B may play a role in fever-triggered cardiac repolarization abnormalities.

Notably, mutated OLFML2B demonstrates a pronounced dominant-negative effect on wildtype protein. In heterozygous states, the wildtype allele cannot compensate for secretion defects caused by the mutant allele, potentially explaining the severe phenotypes observed in SIDS cases with OLFML2B mutations .

Research Methods Using OLFML2B Antibodies

OLFML2B antibodies enable diverse research methodologies to investigate this protein's structure, function, and pathological implications.

Protein Detection and Characterization

Antibody-based detection methods have been instrumental in characterizing OLFML2B:

1. Western blot analysis: Optimal results have been achieved using combinations of monoclonal antibodies such as 7C4 (IgG2a) .

2. Dot blot analysis: Allows rapid screening for OLFML2B presence in various samples .

3. ELISA: Enables quantitative measurement of OLFML2B levels in biological fluids and cell culture supernatants .

Tissue and Cellular Localization

Immunohistochemistry and immunofluorescence utilizing OLFML2B antibodies have:

1. Confirmed OLFML2B expression in human heart tissue .

2. Revealed distribution patterns in cancer tissues, correlating with prognosis .

3. Demonstrated co-localization with interacting partners such as Tenascin C .

Functional Studies

OLFML2B antibodies have supported functional investigations through:

1. Knockdown validation: Confirming reduced OLFML2B expression in gene silencing experiments that demonstrated decreased migration and proliferation of bladder cancer cells .

2. Secretion analysis: Monitoring temperature-dependent secretion behavior of wildtype versus mutant OLFML2B variants .

3. Protein-protein interaction studies: Identifying interaction partners like TNC through co-immunoprecipitation followed by mass spectrometry .

Future Perspectives in OLFML2B Research

The continued development and application of OLFML2B antibodies will likely advance several promising research directions:

Clinical Biomarker Development

Given OLFML2B's strong prognostic associations in multiple cancers, antibody-based diagnostic tests could emerge for patient stratification . Standardized immunohistochemical protocols might provide clinically actionable information regarding cancer prognosis and potential treatment responses.

Therapeutic Target Exploration

The mechanistic connections between OLFML2B and cancer cell behavior, coupled with its role in the tumor microenvironment, suggest potential therapeutic applications . Antibody-drug conjugates or therapies targeting OLFML2B-dependent pathways could represent novel treatment strategies.

Cardiovascular Applications

The connection between OLFML2B mutations and cardiac conditions presents opportunities for genetic screening and risk assessment . Furthermore, understanding temperature-dependent OLFML2B secretion could inform preventive measures for fever-triggered arrhythmias in susceptible individuals.